Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series
- 41 Downloads
Contact immunotherapy with diphenylcyclopropenone (DPCP) and anthralin is considered the treatment option for extensive alopecia areata (AA) unresponsive to DPCP immunotherapy alone. Only one study has described the efficacy of combination therapy; therefore, we investigated whether topical DPCP and anthralin can promote hair regrowth in DPCP-non responders. In this retrospective case-series we analyzed the efficacy and side effects of DPCP with anthralin in AA patients who did not respond to several months of treatment with DPCP alone. Thirty-two DPCP-nonresponsive AA patients were treated with DPCP and anthralin for the average of 8.3 ± 3.8 (3–17) months. During the treatment, 40.62% of patients (13 patients out of 32) had terminal hair regrowth. The mean of hair regrowth rate was 41%; it was mainly as partial hair regrowth (˂ 50%) and 27.27% of cases achieved > 50% terminal hair regrowth. Treatment response strongly related to the duration of combination therapy (p value ˂ 0.001), but we did not find any relation with other demographic characteristics. The first signs of response to treatment were noticed 2–12 months (5.5 ± 3.4) after initiation of combination therapy while there was a positive correlation among the duration of treatment and percentage of hair regrowth (p < 0.001). The most common complication was bullae (25%), and the least frequent side effect was generalized pruritus (3.1%). The combination therapy with DPCP and anthralin could be effective to treat DPCP non-responder AA patients. Additionally, the higher treatment response could be achieved by longer treatment duration.
KeywordsAlopecia areata Diphenylcyclopropenone Anthralin Immunotherapy Side effects
This research has not any funding source.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the Ethics Research Committee of the School of Public Health, Tehran University of Medical Sciences. (IR.TUMS.MEDICINE.REC.1397.154).
- 5.Dall’oglio F, Nasca MR, Musumeci ML, La Torre G, Ricciardi G, Potenza C, Micali G (2005) Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatol Treat 16:10–14. https://doi.org/10.1080/09546630410023601 CrossRefGoogle Scholar
- 7.Durdu M, Özcan D, Baba M, Seçkin D (2015) Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol 72:640–650. https://doi.org/10.1016/j.jaad.2015.01.008 CrossRefGoogle Scholar
- 9.Happle R, Hausen BM, Wiesner-Menzel L (1983) Diphencyprone in the treatment of alopecia areata. Acta Dermato Venereol 63:49–52Google Scholar
- 10.Herbst V, Zoller M, Kissling S, Wenzel E, Stutz N, Freyschmidt-Paul P (2006) Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 16:537–542Google Scholar
- 21.Spano F, Donovan JC (2015) Alopecia areata: part 2: treatment. Can Fam Physician 61:757–761Google Scholar
- 27.Wasylyszyn T, Borowska K (2017) Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: an observational study of nonresponder patients with alopecia areata. Australas J Dermatol 58:219–223. https://doi.org/10.1111/ajd.12478 CrossRefGoogle Scholar